Introduction
Infectious mononucleosis is common among adolescents and young adults. No guidelines for management of mononucleosis have been published. However, the American Academy of Pediatrics recommends that a short course of corticosteroid therapy may be considered for certain serious complications, such as impending airway obstruction, massive splenomegaly, hemolytic anemia, hemophagocytic lymphohistiocytosis, or myocarditis. 2 Although some physicians prescribe prednisone for symptomatic treatment of other manifestations of mononucleosis such as sore throat without airway obstruction, a recent Cochrane reviewidentified no apparent benefit of steroid therapy for uncomplicated mononucleosis 3 ; such treatment is not recommended despite its widespread use.
Sinusitis is a well-recognized complication of viral infections, including mononucleosis.
Corticosteroid therapy, even when only prescribed for brief periods, increases the risk of a variety of bacterial, viral, mycobacterial, and parasitic infections by 60%. 4 Fardet et al. reported a 5.84-fold increased relative hazard of lower respiratory tract infections among patients who received systemic steroid treatment for any reason (the prevalence of upper respiratory tract infections including sinusitis was not studied) 5 .
Arcanobacterium haemolyticum is a slowly growing, facultative anaerobic gram-positive bacillus. 6 Originally named Corynebacterium haemolyticum when recognized as a cause of exudative pharyngitis in US soldiers and natives of the South Pacific in 1946, the organism's name was changed to Arcanobacterium haemolyticum in 1982 after cell wall components and chemotaxonomic features were noted to differ from Corynebacterium spp. Humans are the primary reservoir for A. haemolyticum, which has two biotypes, rough and smooth. The smooth biotype is a cause of pharyngitis in healthy adolescents whereas the rough biotype is associated with a variety of invasive infections which are more commonly seen in immunocompromised adults. 6 The aptly-named Arcanobacterium ("secret bacterium") is difficult to cultivate with conventional culture techniques (i.e., incubation of specimens on sheep's blood agar for 24 hours). One study reported that yield was highest when horse blood agar was utilized and specimens were incubated with supplemental 5% CO 2 incubation for 48 hours. 7 However, community laboratories do not typically use horse blood agar; thus the true prevalence of Arcanobacterium infections is likely higher than has been reported.
We report a case of Epstein-Barr Virus (EBV) mononucleosis treated with prednisone complicated by secondary bacterial sinusitis with intracranial extension leading to brain abscesses and subdural empyema, associated with Arcanobacterium bacteremia. To our knowledge this is the first report of EBV-associated Arcanobacterium haemolyticum brain abscess and subdural empyema.
Case Report
A previously healthy 20-year-old African American male college football player developed sore throat, fatigue, and painful cervical lymphadenopathy. The diagnosis of infectious mononucleosis was established on the basis of a positive heterophile antibody test.
One week later he had worsening sore throat and headache. Prednisone was prescribed for 10 days. Over the following two weeks he had recurrent fevers, chills, malaise, anorexia, and insomnia, but delayed seeking further medical attention because he was busy taking final examinations. His symptoms progressively worsened.
Three days prior to hospitalization he developed global headache, copious green rhinorrhea, recurrent rigors, and severe anorexia. He presented at a hospital emergency department where he appeared acutely ill. Posterior cervical lymph nodes were swollen and tender. No pharyngeal erythema or exudate was noted. No focal deficits were identified on neurologic examination.
His white blood cell count (WBC) was 16,300/µL (64% neutrophils, 24% bands, 7% monocytes, 5% lymphocytes). Total bilirubin was 5. Computerized tomography scan of the head without contrast showed pansinusitis without intracranial masses, edema, or midline shift. Cerebrospinal fluid WBC count was 2,800/ µL (46% neutrophils, 44% lymphocytes), glucose 44 mg/dL, and protein 100 mg/dL. Gram's stain showed no organisms; culture, which was submitted prior to initiation of antibiotic therapy, was negative. Cerebrospinal fluid EBV PCR was positive (not quantified); 16s RNA was negative.
The patient was hospitalized and treated with ceftriaxone, doxycycline, and vancomycin. Pharyngitis is the most commonly recognized form of A. haemolyticum infection. 8 In half of cases a prominent erythematous rash is seen. Arcanobacterium accounts for 2% of cases of pharyngitis in 15 -18 year old healthy males. Several other forms of Arcanobacterium infection have been reported, including sinusitis 9 , pneumonia 10 , bacteremia 11 , meningitis 12 , and brain abscess. 10, [13] [14] [15] Bacteremia is rare. Two cases were identified during a 15-year period at the Karolinska Institute. The association of life-threatening Arcanobacterium infection with a concomitant Epstein Barr virus infection was of interest in our case. In invasive infections such as brain abscess, bacteremia, pneumonia, and Lemierre's syndrome, A. haemolyticum typically acts as a copathogen with other bacteria or viruses, for reasons that remain unclear. 11, 14, 17 Monomicrobial invasive Arcanobacterium infections, in contrast, are uncommon. In a retrospective study, all six patients with Arcanobacterium bacteremia were found to have co-infection with a second bacterial species. 18 The second bacterium presumably acted synergistically with A. haemolyticum to enhance its pathogenicity.
Although both Epstein Barr Virus mononucleosis and A. haemolyticum pharyngitis are encountered most commonly in persons between the ages of 15 -24, concomitant infection has been recognized infrequently. 9, 14, [19] [20] [21] Three cases of A. haemolyticum bacteremia with primary EBV infection have been reported, one of which had secondary bacterial sinusitis and polymicrobial bacteremia. 20 However, this association may be more common than has been widely recognized. A study of 13 patients with A. haemolyticum bacteremia detected heterophile antibody positivity in five cases. 9 Secondary bacterial infections (most commonly caused by beta hemolytic streptococci) are known to be associated with EBV, likely due to either temporary immune suppression or co-pathogenicity. 22, 23 Thus, transient humoral and cell mediated immunosuppression induced by EBV may enhance A. haemolyticum's virulence. 9, 14, 21, 23, 24 Steroid-induced immunosuppression would be expected to exacerbate the severity of EBVArcanobacterium coinfection.
Brain abscess can be caused by bacteria, mycobacteria, fungi, or parasites, and most commonly arises from either contiguous spread of infection, hematogenous seeding, penetrating trauma, or neurosurgical procedures. 25 A variety of bacteria can cause brain abscesses; the implicated organisms vary based on the initial source of infection. Brain abscesses secondary to sinusitis, as in this case, usually are caused by anaerobic and aerobic streptococci, Bacteroides, E. coli, Enterobacter, Klebsiella, Proteus, S. aureus or Haemophilus. 23 However in 13 -25% of cases, brain abscess cultures are negative, likely secondary to antecedent antibiotic exposure or infection with non-cultivable microorganisms. 23, 25 Arcanobacterium haemolyticum is a rare cause of brain abscess; only six cases have been reported previously. Two of these cases were presumed odontogenic infections (one occurred post-dental extraction; a second patient had severe dental caries; 17 a third occurred after penetrating skull trauma in a patient with acute sinusitis. 15 The sources of the other three infections were not identified. 14, 24, 25 The optimal treatment regimen for invasive A. haemolyticum infections has not been determined. Susceptibility testing is not standardized. In vitro data suggest that A. haemolyticum is susceptible to most classes of antibiotics, including penicillins, cephalosporins, clindamycin, carbapenems, macrolides, fluoroquinolones, tetracyclines, rifampin, and vancomycin, and resistant to sulfonamides. 
